Elevance Health Q2 EPS Forecast Reduced by Zacks Research

Elevance Health, Inc. (NYSE:ELV - Free Report) - Equities researchers at Zacks Research lowered their Q2 2025 earnings estimates for shares of Elevance Health in a report issued on Monday, May 5th. Zacks Research analyst K. Dey now forecasts that the company will post earnings per share of $9.36 for the quarter, down from their previous forecast of $9.85. The consensus estimate for Elevance Health's current full-year earnings is $33.96 per share. Zacks Research also issued estimates for Elevance Health's Q3 2025 earnings at $8.37 EPS, FY2026 earnings at $38.78 EPS and Q1 2027 earnings at $13.31 EPS.

Elevance Health (NYSE:ELV - Get Free Report) last announced its earnings results on Tuesday, April 22nd. The company reported $11.97 EPS for the quarter, beating the consensus estimate of $10.60 by $1.37. Elevance Health had a return on equity of 18.28% and a net margin of 3.38%. The business had revenue of $48.77 billion during the quarter, compared to the consensus estimate of $46.26 billion.

A number of other analysts have also recently weighed in on the company. Wells Fargo & Company lowered their price target on Elevance Health from $483.00 to $478.00 and set an "overweight" rating on the stock in a research report on Tuesday, January 28th. Argus set a $465.00 target price on Elevance Health in a report on Friday, April 25th. Guggenheim reaffirmed a "buy" rating and set a $518.00 price target on shares of Elevance Health in a research note on Wednesday, April 23rd. Stephens downgraded Elevance Health from an "overweight" rating to an "equal weight" rating and cut their price objective for the company from $520.00 to $440.00 in a report on Wednesday, January 22nd. Finally, Truist Financial upped their price objective on Elevance Health from $480.00 to $510.00 and gave the company a "buy" rating in a research note on Friday, April 11th. Four research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $510.38.

Elevance Health Stock Performance

NYSE ELV traded down $7.86 during trading on Wednesday, hitting $404.52. The company's stock had a trading volume of 948,113 shares, compared to its average volume of 1,472,531. The firm has a 50 day moving average price of $424.13 and a 200 day moving average price of $404.51. The company has a quick ratio of 1.50, a current ratio of 1.45 and a debt-to-equity ratio of 0.71. The firm has a market cap of $91.40 billion, a P/E ratio of 15.80, a price-to-earnings-growth ratio of 1.18 and a beta of 0.66. Elevance Health has a 52 week low of $362.21 and a 52 week high of $567.26.

Elevance Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, June 25th. Stockholders of record on Tuesday, June 10th will be given a $1.71 dividend. This represents a $6.84 annualized dividend and a dividend yield of 1.69%. The ex-dividend date is Tuesday, June 10th. Elevance Health's payout ratio is presently 26.69%.

Insiders Place Their Bets

In other news, CAO Ronald W. Penczek sold 443 shares of the stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $415.13, for a total value of $183,902.59. Following the completion of the sale, the chief accounting officer now owns 1,847 shares of the company's stock, valued at approximately $766,745.11. This represents a 19.34 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Mark Kaye sold 4,588 shares of the stock in a transaction on Thursday, April 24th. The stock was sold at an average price of $424.82, for a total transaction of $1,949,074.16. Following the sale, the chief financial officer now owns 18,977 shares of the company's stock, valued at approximately $8,061,809.14. This trade represents a 19.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 8,535 shares of company stock worth $3,521,612 over the last three months. Insiders own 0.29% of the company's stock.

Institutional Investors Weigh In On Elevance Health

Several institutional investors and hedge funds have recently made changes to their positions in the business. Chicago Partners Investment Group LLC bought a new stake in Elevance Health during the 1st quarter valued at $263,000. Charles Schwab Investment Management Inc. grew its position in Elevance Health by 6.6% in the first quarter. Charles Schwab Investment Management Inc. now owns 1,782,653 shares of the company's stock worth $775,383,000 after acquiring an additional 109,628 shares in the last quarter. ASR Vermogensbeheer N.V. purchased a new stake in Elevance Health during the first quarter valued at about $11,260,000. Strategy Asset Managers LLC boosted its holdings in shares of Elevance Health by 2.1% during the first quarter. Strategy Asset Managers LLC now owns 5,858 shares of the company's stock worth $2,548,000 after purchasing an additional 118 shares during the period. Finally, Hemington Wealth Management raised its holdings in Elevance Health by 13.3% in the 1st quarter. Hemington Wealth Management now owns 230 shares of the company's stock worth $100,000 after purchasing an additional 27 shares in the last quarter. Institutional investors own 89.24% of the company's stock.

About Elevance Health

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.